Acute Pancreatitis Market Report 2026

The acute pancreatitis market size has grown strongly in recent years. It will grow from $6.29 billion in 2025 to $6.67 billion in 2026 at a compound annual growth rate (CAGR) of 6%. The growth in the historic period can be attributed to increasing prevalence of gallstone-related disorders, high alcohol consumption rates, limited awareness of early pancreatitis symptoms, conventional imaging and laboratory diagnostic usage, growing hospital and clinic patient base.

The acute pancreatitis market size is expected to see strong growth in the next few years. It will grow to $8.55 billion in 2030 at a compound annual growth rate (CAGR) of 6.4%. The growth in the forecast period can be attributed to development of targeted therapeutic interventions, rising awareness of lifestyle modifications, adoption of minimally invasive treatments, growth in hospital and clinic capacities, integration of advanced diagnostic technologies. Major trends in the forecast period include rising incidence of gallstone and alcohol-induced pancreatitis, increased use of advanced imaging and laboratory diagnostic tests, growing adoption of intravenous fluid and nutritional support treatments, expansion of minimally invasive procedures like ercp, enhanced focus on early detection and patient management strategies.

Increasing healthcare expenditure is expected to drive the growth of the acute pancreatitis market going forward. Healthcare expenditure refers to the total resources, both financial and non-financial, utilized in providing health services and related activities. Rising healthcare expenditure can be attributed to factors such as the prevalence of chronic diseases, expanded health insurance coverage, and increased awareness of mental health issues. Acute pancreatitis can result in serious complications, including necrotizing pancreatitis, organ failure, and infections, requiring additional treatments, surgeries, and extended hospital stays, which significantly increase healthcare costs. For instance, in November 2023, according to the Canadian Institute for Health Information, a Canada-based non-profit organization, total health expenditure in 2023 was projected to reach $344 billion, reflecting a modest 2.8% increase compared to the previous year. Therefore, rising healthcare expenditure is fueling the growth of the acute pancreatitis market.

Major companies operating in the acute pancreatitis market are developing advanced technologies, such as dry chemistry slide technology, to accurately measure pancreatic lipase levels. Dry chemistry slide technology is a diagnostic method that uses slides coated with dry reagents to perform chemical reactions for analyzing biological samples, allowing for rapid and precise testing without liquid reagents. For instance, in June 2024, IDEXX Laboratories Inc., a US-based diagnostics and healthcare innovation company, launched the catalyst pancreatic lipase test for diagnosing pancreatitis in dogs and cats, using dry chemistry slide technology for accurate pancreatic lipase measurement. The test delivers rapid, quantitative results in under 10 minutes and integrates seamlessly with existing workflows, improving diagnostic efficiency. It aims to facilitate early diagnosis and treatment of pancreatitis in pets and will be further enhanced by future developments such as the Catalyst SmartQC Control to streamline veterinary diagnostics.

In March 2023, CalciMedica Inc., a US-based biopharmaceutical company, merged with Graybug Vision for an undisclosed amount. The merger aims to advance the development of CalciMedica's lead product candidate, Auxora, for treating life-threatening inflammatory diseases, particularly acute pancreatitis, by combining resources and expertise. Graybug Vision Inc. is a US-based biopharmaceutical company focused on developing innovative therapies for ocular diseases.

Major companies operating in the acute pancreatitis market are CalciMedica Inc., SCM Lifescience Co. Ltd., Baxter International Inc., B. Braun Melsungen AG, Medtronic plc, Boston Scientific Corporation, Fresenius Kabi AG, Sun BioPharma Inc., Atox Bio Inc., D-Pharm Ltd., Olympus Corporation, Abbott Laboratories, Pfizer Inc., Merck & Co Inc., GlaxoSmithKline plc, AbbVie Inc., Amgen Inc., AstraZeneca PLC, Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche AG, Novartis AG, Sanofi SA, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., Johnson & Johnson.

North America was the largest region in the acute pancreatitis market in 2025. The regions covered in the acute pancreatitis market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the acute pancreatitis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have impacted the acute pancreatitis market by increasing costs for imported medical devices, imaging equipment, and intravenous therapy supplies. Segments such as ERCP devices, imaging systems, and infusion sets are most affected, particularly in Asia-Pacific and North American regions. These tariffs have led to higher treatment costs and supply chain adjustments. On the positive side, they encourage local manufacturing, domestic production of medical equipment, and innovation in cost-effective therapeutic solutions.

The acute pancreatitis market research report is one of a series of new reports that provides acute pancreatitis market statistics, including acute pancreatitis industry global market size, regional shares, competitors with a acute pancreatitis market share, detailed acute pancreatitis market segments, market trends and opportunities, and any further data you may need to thrive in the acute pancreatitis industry. This acute pancreatitis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Acute pancreatitis is a medical condition in which the pancreas becomes inflamed and enlarged over a short period. It is commonly caused by gallstones or excessive alcohol consumption.

The main causes of acute pancreatitis are gallstones, alcohol, and others. Gallstones are solidified bile deposits that can form in the gallbladder. They cause pain and inflammation of the pancreas when a gallstone obstructs the pancreatic duct, leading to acute pancreatitis. Treatments for acute pancreatitis include intravenous fluids, nutritional support, analgesics, endoscopic retrograde cholangiopancreatography (ERCP), and others. Diagnosis is carried out through imaging tests and laboratory tests, and treatment is provided by hospitals, clinics, and other healthcare facilities.

The acute pancreatitis market includes revenues earned by entities by providing therapies, medications, and procedures aimed at managing and treating the condition. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.